Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Tellingly, Teva And Lonza Part Ways

Executive Summary

Teva and Lonza agree to dissolve their four-year-old biosimilars joint venture, created at a time when the biosimilars opportunity seemed huge, if vague. In an otherwise slow deal-making week, next-generation antibody platform company Adimab forged two transforming deals with GSK and Biogen, while Kolltan and the Children’s Hospital of Philadelphia plunged into neuroblastoma.

You may also be interested in...



Korea’s Celltrion Dismisses As Rumor Reports That AstraZeneca, Roche And Teva Are Interested Buyers

Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.

Deals Of The Week Searches For Meaning In Deal Break-Ups

Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.

Deals Of The Week: How Do 2013 Biotech Deal Stats Stack Up After Amgen/Onyx?

A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel